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Abstract
This article aims to describe the inappropriate use of medicines in the Brazilian urban population
and to identify associated factors. We conducted a data analysis of a household survey carried out
in Brazil in 2013–14. The sampling plan was done by clusters with representativeness of the urban
population and large regions of the country, according to gender and age domains. For this ana-
lysis, we considered a sample of adults (20 years) who reported having chronic non-
communicable diseases, medical indication for drug treatment and medicine use (n¼12 283). We
evaluated the prevalence of inappropriate use in the domains: non-adherence, inappropriate use
behaviour and inadequate care with medicines, all verified in the following groups of independent
variables: demographic and socio-economic characteristics, health and pharmaceutical care,
health status and use of medicines. Crude and adjusted prevalence ratios were obtained using ro-
bust Poisson regression. It was found 46.1% of people having at least one behaviour of inappropri-
ate use of medicines. The worst results were found for the domain of inappropriate use behaviour,
a situation of 36.6% of the users, which included unauthorized prescriber, inadequate source of in-
formation and indication of the medicines by non-authorized prescribers. The best result was found
for the lack of medicines care, informed by only 4.6% of users who kept expired drugs at home.
The inappropriate use of medicines was associated with gender (female), region of residence
(Northeast), not visiting the doctor regularly or visiting more than one doctor, not having free ac-
cess to medicines and using of five or more medicines. There was a high prevalence of inappropri-
ate use, which was associated with both individual and health system characteristics pointing out
the need to set priorities as for health education and public interventions.
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Background
The appropriate use of medicines (AUM) is inalienably linked to ac-
cess to medicines as an important health system goals, both funda-
mental to achieve universal access to health care and coverage
(Wirtz et al., 2017). When proposing the six building blocks of a
health system, the assurance of equitable access to essential medical
medicines, vaccines and technologies of assured quality, safety, effi-
cacy and cost-effectiveness is together with the assurance of their sci-
entifically sound and cost-effective use (WHO, 2007).
The medication process involves a wide set of stakeholders from
inside, as prescribers, dispensers, care keepers and patients, as well
as from outside the health system, as medicines producers and ven-
dors. However, the patients, the ones who really deal with the con-
sequences of medicines use, should be at the core of health system
efforts. Household surveys provide a unique opportunity to capture
users perspectives (Short Fabic et al., 2012) and can be applied in
regards to the practices and experiences related to medicines
(Mengue et al., 2016).
The World Health Organization, as well as other broad initia-
tives, as ‘Medicines Transparency Alliance’ have been investing on
medicines use studying methods which are suitable to be applied in
low- and middle-income countries, that generally do not count on
robust and well-structured information systems on this issue. The
most developed approach is the one applied in healthcare facilities
(WHO, 2006). It has been valuable to show problems regarding
availability of medicines, storage conditions and some issues regard-
ing appropriate use problems perceivable at the health facility level,
as adherence of prescribers to standard treatment protocols and the
average number of medicines per prescription (WHO, 2009). A
household approach also exists, enabling countries to raise relevant
information (WHO, 2016).
Nevertheless, there is still the need for indicators able to point
out relevant group of problems in order to monitor and guide pol-
icymaking addressing the promotion of AUM. As an example, des-
pite the access to medicines being a target among the Millennium
Development Goals, there is no indicator to monitor it (Gotham
et al., 2016).
Intending to start a monitoring system on pharmaceutical poli-
cies, the Brazilian Ministry of Health promoted the conduction of a
National Survey on Access, Use and Promotion of Rational Use of
Medicines (PNAUM) with two components: evaluation of the dis-
pensing facilities and a household survey.
Both were able to raise interesting data on the access and use of
medicines. It was found 94.3% [95% confidence interval (CI):
93.4–95.1] of full access to non-communicable diseases (NCDs)
medicines, 30.8% (95%CI: 28.8–33.0) of low adherence prevalence
to drug treatment for NCD (Tavares et al., 2016) and 16.1%
(95%CI: 15.0–17.5) of self-medication (Arrais et al., 2016).
Nevertheless, a synthetic indicator on the AUM has not been pre-
sented until now, and it is considered potentially useful to facilitate
its monitoring strategies.
In this article, we aim to describe the inappropriate use of medi-
cines in the Brazilian population at a household level using a syn-
thetic indicator, identifying associated variables.
Methods
We used data from the National Survey on Access, Use and
Promotion of Rational Use of Medicines (PNAUM—Pesquisa
Nacional Sobre Acesso, Utilizaç~ao e Promoç~ao do Uso Racional de
Medicamentos) a nationwide household survey with a representative
sample of the Brazilian urban population at national and adminis-
trative regions level. Since the use of medicines varies according to
age and gender, the sampling considered a balance of these two vari-
ables. The results were adjusted by post-stratification weights con-
sidering the low response taxes. The data were collected between
September 2013 and February 2014. More details on the PNAUM
methods can be found elsewhere (Mengue et al., 2016).
The study population for this analysis was of 12 283 people aged
20 years or more who reported being informed by a physician to
have a chronic disease (NCD), reported receiving indication to treat
it with medicines and being in use of these medicines.
The inappropriate use of medicines was evaluated considering
the report of at least one inappropriate behaviour on the use of med-
icines. The analysed misbehaviours were classified in three groups as
follows: (1) Non-adherence, which includes (i) therapy interruption,
(ii) missed doses, (iii) reduction of doses and (iv) taking extra doses;
(2) inadequate medicine use behaviour, which includes (i) medicines
indicated by other people besides doctors and dentists, (ii) informa-
tion about medicines in non-reliable sources and (iii) indication of
medicines to other people; and (3) Inadequate care with medicines,
which considers keeping expired medicines at home.
These indicators were adapted from Mendes et al. (2014), who
proposed a composite indicator to evaluate the AUM by hyperten-
sive and/or diabetic patients treated in primary healthcare units in
the city of Rio de Janeiro. This indicator was constructed from dif-
ferent theoretical constructs, whose information came from different
sources: direct observation of the field researchers, interviewees’
reports from dichotomous questions, multiple choice and Likert
scale and combined three domains (adherence, auto-medication and
Key Messages
• About half of people had at least one inappropriate medicines use behaviour.
• The inappropriate use of medicines was associated both with the characteristics of the individuals, treatment, and of the
health system.
• Our results point out the need to enforce health education of individuals, families and community regarding to medi-
cines as well as health system strengthening measures.
• This study proposes a synthetic indicator to inappropriate use of medicines, after application in a national household
survey data.
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adequate behaviour regarding medicines—ask for information only
to health professionals, no expired medicines neither damaged medi-
cine package or label, all medicines prescribed by authorized pre-
scribers). More information is available in the published article.
The independent variables under analysis were: sex (male, female);
age group (20–39, 40–59, 60 years old or more); skin colour (white,
non-white); marital status (married, single); years of formal education
(0, 1–8, 8 or more); economic classification (A/B, C, D/E) according to
the Brazilian Economic Classification Criterion of the Brazilian
Association of Research Companies (CCEB 2013/ABEP—Associaç~ao
Brasileira de Empresas de Pesquisa (http://www.abep.org/); residential
geographical region (North; Northeast; Southeast; South, Midwest);
health insurance (yes, no); visiting the doctor to treat chronic diseases
(no, yes one, yes more than one); free access to the medicines to treat
chronic diseases (all, some, none); hospitalization in the previous year
(no, once, two or more times); emergency care visits in the previous
year (no, once, two or more times); health perception (very good, good,
regular, bad, very bad); the number of chronic diseases (1, 2, 3 or
more); limitation caused by chronic diseases (yes, no); the number of
medicines in use (1, 2, 3–4, 5 or more) (Figure 1).
An exploratory descriptive analysis was conducted; in addition
to the prevalence estimates, 95% confidence intervals (95%CI) were
calculated and the Pearson’s chi-square test was applied to assess the
statistical significance of the differences among the groups, consider-
ing a 5% level of significance.
The Poisson regression model was used to estimate the crude and
adjusted prevalence ratios (PR), and the 95%CI, to the aggregate as
well as to single component’s outcomes. We attempted to control pos-
sible confounding factors in the multivariate analysis, using a hierarch-
ical analysis model (Figure 1). Variables with P<0.20 were included in
the multiple model and a significance level of 5% was adopted to main-
tain the variables in the model, along with a backward selection of the
variables. The statistical significance of the PR obtained from the
Poisson regression models was evaluated using the Wald test.
The analyses were conducted with Stata V.12, using the set of
svy commands to analyse complex samples and guaranteed the
required weighting by contemplating the characteristics of the sam-
ple design that used different sampling fractions and post-
stratification weights to correct the response rate flaw.
The study’s design was submitted and approved by the National
Ethical Research Committee (CONEP). All the interviews were con-
ducted after the respondent or his/her legal guardian had signed an
informed consent term.
Results
Regarding the socio-economic-demographic characteristics, the
weighted estimates indicated that half of the respondents
self-declared themselves as white skin colour, there was a higher
prevalence of women (64.8%), adults aged between 40 and 59 years
(42.7%), married (61.4%), with time spent in education between 1
and 8 years (42.8%), 54.6% belonging to economic class C, 51.4%
residing in the Southeast region and 71.9% having no health insur-
ance. Regarding the health services utilization, the majority of the
respondents reported visiting the doctor to treat chronic diseases
(62.6%), having free access to the medicines (46.7%), not being hos-
pitalized in the previous year (89.2%) or visiting the emergency in
the previous year (76.4%). Regarding health perception and dis-
eases, most of the respondents said their health was good (45.3%)
or regular (41.2%), 45.6% reported one chronic disease and 84.2%
declared having limitations caused by their chronic diseases.
Considering the use of medicines, the majority was in use of three or
more medicines at the time of the interview (54.4%) (Table 1).
The prevalence of inappropriate use of medicines was 46.1%.
From these, 55.3% reported only one misbehaviour, 27.8%
reported two and 16.9% three or more. With reference to the inad-
equate use domains, the highest prevalence was found on the non-
adherence (31.9%) group, with greater and smallest highlights in
the proportion of people that reduced medication doses (19.8%)
and the proportion of people who took an extra dose or more medi-
cation than prescribed (7.4%). Following, the prevalence found for
the inadequate medicine use behaviour domain was 36.6%, in
which the highest and smallest prevalence was found in the indica-
tors that considered the proportion of people who had their medi-
cines indicated by other people besides doctors and (34.3%) and the
indication of medicines to other people (7.4%). Finally, the smallest
prevalence, meaning the best result for the inadequate use of medi-
cines, was found for the domain that considers the inadequate care
with medicines, with 4.6% of the respondents with expired medi-
cines at home (Table 2).
Figure 1. Hierarchical analysis model of the studied factors and its associations to the inappropriate use of medicines. PNAUM, Brazil, 2014. Source: adapted
from Tavares et al. (2016).
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Table 1 Sample distribution and prevalence of inappropriate use of medicines according to demographic, socio-economic and health sys-
tem characteristics, health perception, diseases and use of medicines
Variables Sample distribution Proportion of inappropriate medicine use
% 95%CI % 95%CI
Demographic characteristics
Sex <0.001a
Male 35.2 33.9–36.6 39.4 36.1–42.9
Female 64.8 63.4–66.1 49.8 46.8–52.7
Age group (years) <0.001a
20–39 16.3 14.8–17.9 57.5 52.3–62.5
40–59 42.7 41.1–44.3 46.3 43.0–49.6
60 41.0 39.2–42.8 41.5 38.5–44.5
Skin colorb 0.001a
White 50.1 47.3–52.9 43.1 39.9–46.3
Non-white 49.9 47.1–52.7 48.4 45.0–51.9
Marital statusb 0.021a
Married 61.4 59.8–62.9 44.8 41.6–48.0
Single 38.6 37.1–40.2 48.4 45.1–51.6
Socio-economic characteristics
Education (years)b 0.153a
0 15.2 13.9–16.6 47.0 42.9–51.2
1–8 42.8 40.9–44.7 44.4 41.0–47.9
8 42.0 40.1–43.9 47.6 44.2–51.0
Economic classificationc 0.636a
A/B 24.5 22.2–26.9 47.5 43.0–52.1
C 54.6 52.7–56.5 45.5 42.3–48.7
D/E 20.9 19.1–22.8 46.3 42.0–50.7
Region <0.001a
North 4.4 3.4–5.6 44.7 39.0–50.4
Northeast 21.2 17.3–25.7 61.3 57.5–64.9
Southeast 51.4 45.5–57.3 41.9 37.1–47.0
South 15.4 12.4–18.9 38.3 35.2–41.5
Midwest 7.7 6.0–9.8 49.0 45.3–52.7
Health insurance (private)b 0.904a
Yes 28.1 25.7–30.7 46.3 42.2–50.6
No 71.9 69.3–74.3 46.1 43.0–49.2
Health service utilization characteristics
Visit the doctor to treat chronic diseasesb <0.001a
No 7.9 6.9–9.0 66.7 61, 1–71, 8
Yes, one 62.6 60.5–64.6 41.7 38, 5–44, 9
Yes, more than one 29.5 27.9–31.2 51.8 48, 4–55, 2
Free access to the medicines to treat chronic diseasesb <0.001a
All 46.7 44.3–49.1 41.4 38, 0–45, 0
Some 20.2 19.0–21.4 49.3 45, 1–53, 5
None 33.1 31.0–35.3 49.1 45, 9–52, 2
Hospitalized in the previous yearb 0.180a
No 89.2 88.3–90.0 45.8 42, 9–48, 8
Once 8.2 7.5–9.0 48.0 43, 1–53, 0
Two or more times 2.7 2.2–3.1 53.1 45, 1–61, 0
Emergency visits in the previous yearb <0.001a
No 76.4 74.6–78.0 43.1 40, 1–46, 1
Once 15.4 14.3–16.5 54.5 50.3–58.5
Two or more times 8.3 7.3–9.3 59.2 54.2–63.9
Health perception and diseases
Health perception <0.001a
Very good 5.1 4.4–5.8 42.4 34.7–50.4
Good 45.3 43.3–47.2 41.0 37.6–44.4
Regular 41.2 39.5–12.9 50.3 47.0–53.6
Bad 6.3 5.6–7.0 54.2 49.4–59.0
Very bad 2.2 1.9–2.6 59.1 50.9–66.9
Number of chronic diseases <0.001a
1 45.6 43.7–47.5 41.1 37.8–44.5
2 27.1 25.9–28.2 47.5 44.4–50.7
3 or more 27.3 25.7–29.0 53.1 49.3–56.9
(continued)
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The bivariate analysis shows a higher inappropriate use of medi-
cines in women (49.8%), aged between 20 and 39 years (57.5%), non-
white skin colour (48.4%), single (48.4%), residing in the Northeast
region of Brazil (61.3%), who didn’t visit the doctor to treat their
chronic diseases (66.7%), with free access to medicines (49.3%) and
who reported having limitations caused by chronic diseases (47%).
The number of emergency visits in the previous year, health perception,
number of chronic diseases and use of medicines showed proportional
gradients to the inappropriate use of medicines; the highest prevalence
were: two or more emergency visits in the previous year (59.2%) very
bad health perception (59.1%), three or more chronic diseases
(53.1%) and five or more medicines in use (56.5%). The number of
hospitalizations in the previous year, the economic classification, edu-
cation and health insurance didn’t have a statistically significant rela-
tion to the inappropriate use of medicines (Table 1).
In regards to the multivariable analysis, performed through Poisson
regression, the inappropriate use of medicines profile was found as fol-
lows: women (PR¼1.21), ages between 20 and 39years (PR¼1.44),
residing in the Northeast region of Brazil (PR¼1.19), who reported not
visiting the doctor to treat chronic diseases (PR¼1.30; 95%CI: 1.18–
1.44), with no free access to medicines (PR¼1.14), with two or more
emergency visits in the previous year (PR¼1.12) and five or more medi-
cines users (PR¼2.0). Besides that, an important variation between the
crude and adjusted PR was found in the following variables: ‘Northeast
Table 1 (continued)
Variables Sample distribution Proportion of inappropriate medicine use
% 95%CI % 95%CI
Limitation caused by chronic diseasesb 0.036a
Yes 84.2 83.0–85.4 47.0 44.4–49.9
No 15.8 14.6–17.0 42.8 38.4–47.2
Use of medicines
Number of medicines in use <0.001a
1 21.6 20.3–22.9 34.8 31.4–38.3
2 24.0 20.3–22.9 42.7 38.6–47.0
3–4 30.9 293–32.3 48.8 45.5–52.2
5 or more 23.5 22.0–25.0 56.5 52.6–60.3
Total 46.1 43.3–49.0
Percentages adjusted by sample weights and post-stratification according to age and gender. Pnaum, Brazil, 2014 (N¼ 12 283).
aPearson’s chi-square test.
bVariable with missing values.
cThe Economic Classification variable is according to the 2013 Brazilian Economic Classification Criterion of the Brazilian Association of Research Companies
(www.abep.org).
Table 2 Inappropriate use of medicines domains and its indicators of analysis along with its prevalence in the study population
Indicator Origin variable % LCEMPa
IMU 1 Non-adherence
At least one inadequate behaviour from the list above (UAM1)
31.9
IMU 1.1 Proportion of people who interrupted therapy Remained without medicines for the treatment of
your chronic diseases in the last 30 days?
9.9 Underuse
IMU 1.2 Proportion of people who reported any missed
doses for chronic treatments
Did you forget any dose in the last week or month? 8.5 Underuse
IMU 1.3 Proportion of people who reduced medication
doses
Do you reduce medication dose when the disease is
controlled, when the medicines makes you fill
bad, when you want it to last longer or when it is
expensive?
19.8 Underuse
IMU 1.4 Proportion of people who took any extra dose or
more medication than prescribed
Do you increase medication dose when you want to
start a stronger treatment, when you notice im-
provement or when you feel worse?
7.4 Overuse
IMU 2 Inadequate medicine use behaviour
At least one inadequate behaviour from the list above (UAM2)
36.6
IMU 2.1 Proportion of people who had their medicines
indicated by other people besides doctors and dentists
Who indicated this medicine? 34.3 Misuse
IMU 2.2 Proportion of people who sought for information
about medicines in non-reliable sources such as relatives
or other people and services not related to health
When you have any questions about using medi-
cines, where or with whom you usually seek for
information?
5.9 Misuse
IMU 2.3—Indication of medicines to other people Did you indicate this medicine to other people? 17.7 Misuse
IMU 3 inadequate care with medicines
At least one expired medicine (UAM3)
4.6
IMU 3.1 Proportion of people with at least one expired
medicine
Expire date of the medicine 4.6 Misuse
PNAUM, Brazil, 2014 (N¼ 12 283).
aThe Lancet Commission on Essential Medicines Policies.
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Table 3 Crude and adjusted PR on the inappropriate use of medicines and its components (non-adherence, inadequate medicine use behav-
iour and inadequate care with medicines) according to demographic, socio-economic and health system characteristics, health perception,







Crude PR Adjusted PRa Adjusted PRa Adjusted PRa Adjusted PRa
RP CI95% RP CI95% RP CI95% RP CI95% RP CI95%
Demographic characteristics
Sex <0.001b <0.001b <0.001b <0.001b
Male Ref. Ref. Ref. Ref.
Female 1.26 1.18–1.35 1.21 1, 14–1, 29 1.18 1.09–1.29 1.37 1.21–1.55
Age group (years) <0.001b <0.001b <0.001b <0.001b
20–39 1.38 1.26–1.52 1.44 1, 31–1, 58 1.74 1.53–1.98 1.56 1.30–1.88
40–59 1.12 1.05–1.19 1.14 1, 07–1, 21 1.19 1.09–1.30 1.18 1.05–1.33












Economic classificationd 0.647b 0.039b
A/B Ref. Ref.
C 0.96 0.87–1.06 0.89 0.77–1.04
D/E 0.97 0.86–1.10 0.80 0.67–0.95
Region <0.001b <0.001b <0.001b <0.001b
North Ref. Ref. Ref. Ref.
Northeast 1.37 1.19–1.58 1.19 1.05–1.35 1.24 1.05–1.45 1.12 0.93–1.34
Southeast 0.94 0.79–1.12 0.88 0.75–1.02 0.88 0.73–1.06 0.76 0.62–0.93
South 0.86 0.74–1.0 0.83 0.72–0.95 0.82 0.69–0.97 0.69 0.55–0.85





Visit the doctor to treat
chronic diseasesc
<0.001b <0.001 <0.001b <0.001b 0.005b
No 1, 29 1, 17–1, 41 1, 31 1, 19–1, 45 1.26 1.11–1.43 1.62 1.36–1.92 1.88 1.23–2.89
Yes, one 0, 80 0, 75–0, 86 0, 90 0, 85–0, 97 0.80 0.73–0.88 0.97 0.86–1.08 1.00 0.73–1.37
Yes, more than one Ref. Ref. Ref. Ref. Ref.
Free access to the medicines
to treat chronic diseasesc
0.011b 0.001 <0.001b
All Ref. Ref. Ref.
Some 1.19 1.10–1.29 0.98 0.91–1.05 0.85 0.74–0.99
None 1.18 1.09–1.29 1.14 1.05–1.23 1.27 1.12–1.43
Hospitalized in the previous yearc 0.108b 0.014b
No Ref. Ref.
Once 1.05 0.95–1.16 0.80 0.68–0.96
Two or more times 1.16 1.0–1.35 0.78 0.59–1.05
Emergency visits in the
previous yearc
<0.001b 0.012 <0.001b
No Ref. Ref. Ref.
Once 1.26 1.17–1.36 1.09 1.01–1.17 1.14 1.04–1.26
Two or more times 1.37 1.25–1.50 1.12 1.03–1.22 1.21 1.08–1.36
(continued)
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region’ (crude PR¼1.37 vs adjusted PR¼1.19), ‘two or more times
emergency visits in the previous year’ (crude PR¼1.37 vs adjusted
PR¼1.12) and ‘5 or more medicines in use’ (crude PR¼1.62 vs
adjusted PR¼2.00) (Table 3). The model applied to the aggregate in-
appropriate use of medicines outcome translates the behaviour of the
single components to all independent variables, implying a good consist-
ency of the contribution of components to the composite indicator.
Despite statistical significance of the economic classification
variable regarding inadequate medicine use behaviour component,
this was not translated to the aggregate indicators, neither to the
other components (Table 3).
From the analysis of the separate models for each component
(Table 3), we found a more expressive effect in the single components
but more attenuated in the aggregate indicator for the variable ‘Visit
the doctor to treat chronic diseases’ where adjusted PR is 1.3 for the
aggregate outcome and reaches 1.9 for component 3 (drug use with
expired date). On the other hand, the adjusted PR of 0.8 seems to be
protective in relation to non-adherence for those who made at least
one visit compared with those who did not. No significant result for
the adjusted PR of the variable number of chronic diseases to the ag-
gregate indicator was found, but a positive to the non-adherence and
protective effect to the inadequate behaviour was estimated (Table 3).
Discussion
The Lancet Commission on Essential Medicines proposes a tax-
onomy for the inappropriate use of medicines classified in four
categories: unnecessary medicine use (overuse); incorrect medicines
use (misuse); failure to use needed medicines (underuse); and un-
necessary use of highly priced medicines (Wirtz et al., 2017). In this
current article, we were able to approach the first three categories
using a secondary database from a household survey through a syn-
thetic indicator, potentially contributing to the possibility of include
this approach in a monitoring system.
There is an effort in Brazil to build longitudinal databases on
medicines use. From the two main medicines provision mechanisms
in place, ‘Farmacia Popular Program’ counts on a well-structured
database, but it is not that easy to be accessed by researchers (Luiza
et al., 2018) and there is an on-going, but still incomplete, effort to
implement ‘Horus’ (Costa and Nascimento, 2012), a pharmacy
management software which offers data on medicines provision in
public health facilities. Then, PNAUM, was the first study able to
offer a broad picture on access to and use of medicines at national
and regional level (Bertoldi et al., 2016).
In PNAUM, we already achieved a synthetic indicator on access
to medicines to treat NCDs that have been increasingly used in the
country. Despite approaching different aspects of inappropriate use
of medicines in previous publications, we were still missing an
equivalent synthetic indicator to it.
Mendes et al. (2014) proposed a composite indicator to esti-
mate the AUM combining three domains (adherence, no auto-
medication and adequate behaviour regarding medicines—ask for
information only to health professionals, no expired medicines nei-








Crude PR Adjusted PRa Adjusted PRa Adjusted PRa Adjusted PRa
RP CI95% RP CI95% RP CI95% RP CI95% RP CI95%
Health perception and diseases
Health perception <0.001b 0.003b
Very good Ref. Ref.
Good 0.97 0.81–1.16 0.55 0.22–1.41
Regular 1.19 0.99–1.42 0.70 0.27–1.78
Bad 1.28 1.05–1.56 0.96 0.37–2.51
Very bad 1.40 1.16–1.68 1.58 0.53–4.71
Number of chronic diseases <0.001b <0.001b 0.017b
1 Ref. Ref. Ref.
2 1.16 1.08–1.24 1.25 1.13–1.38 0.84 0.73–0.97







Number of medicines in use <0.001b <0.001b <0.001b
1 Ref. Ref. Ref. Ref.
2 1.23 1.11–1.37 1.39 1.23–1.57 3.61 2.66–4.92 1.69 0.86–3.32
3–4 1.40 1.29–1.53 1.64 1.47–1.82 5.95 4.50–7.87 3.91 2.07–7.41
5 or more 1.62 1.46–1.80 2.00 1.77–2.26 8.14 6.0–11.05 7.33 4.02–13.40
PR adjusted by sample weights and post-stratification according to age and gender. Pnaum, Brazil, 2014. (N¼ 12 283).
aVariable selection based on backward deletion (variables with P< 0.20 were included in multiple model and a significance level of 5% was adopted to main-
tain the variables in the model).
bWald’s test.
cVariable with missing values.
dThe Economic Classification variable is according to the 2013 Brazilian Economic Classification Criterion of the Brazilian Association of Research Companies
(www.abep.org).
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by authorized prescribers) and applied in data from a household
survey conducted in Rio de Janeiro (about 6.3 million inhabitants).
In this article, we adapted their proposal to have a picture of the
whole country.
The distribution of the respondents’ characteristics variables
expressed challenges faced on healthcare utilization behaviour and
access, country inequities as well as some health system achieve-
ments at that time to mitigate inequity. The sample comprises peo-
ple reporting the diagnosis of NCD (access to healthcare), medicine
prescription and medicine use (access to medicines). The data sug-
gest, as e.g. a highest proportion of women which is linked to the
fact that they are the most frequent health services users (Levorato
et al., 2014). In the same way, the majority being from the Southeast
region points out inequalities in health services distribution (Viacava
and Bellido, 2016), and in consequence, of diagnosis capacity. The
distribution pattern of other variables as skin colour and private
health insurance coverage show improvements in equity.
The results showed around half people presenting at least one in-
appropriate medicines use behaviour, non-adherence and inad-
equate use were the highest ones. Non-adherence to medication was
shown to be one of the main components of the inadequate use indi-
cator analysed. The low adherence to the drug treatment for chronic
diseases in Brazil is relevant, with regional and demographic differ-
ences and related to the healthcare of the patients pointing to the
need of monitoring strategies in the health services (Tavares et al.,
2016).
Most of the problems in non-adherence domain were linked to
dosage reduction/interruption of treatment, which may be linked to
access to medicines problem. Indeed, the literature reports contro-
versial results on access to medicines. Despite the prevalence of gen-
eral access to NCD medicines is high, from 82.5% (Stopa et al.,
2017) to 94.3% (Oliveira et al., 2016), it varies mainly in regards to
the disease, the number of disease conditions and the user’s living
country or region (Oliveira et al., 2016).
We found a high prevalence of people using non-formal sources
for medicines prescription (in Brazil, legal prescribers are physicians,
dentists and nurses, these last in some specific cases). These prescrip-
tion sources include a huge varied of possibilities as family, neigh-
bours, private pharmacy clerks (there is no legal requirement for
minimal training in Brazil) and internet. Despite the problems linked
to each of these, the last calls for attention, it is an increasing source
of health self-care, including self-medication, with a big variety on
quality of information among websites. Indeed, Gondim et al.
(2012) documented the generally poor quality of information about
medicines on Brazilian websites.
The adjusted prevalence rate did not show an association of in-
appropriate use of medicines and economic classification or educa-
tion, suggesting that equity policies applied around the time of data
collection could have been successful (Luiza et al., 2016).
Independent variables found to be linked to the inappropriate
use of medicines offer information on where to prioritize attention
and efforts to mitigate this problem. As an example, demographic
characteristics indicate whose user profile should be prioritized in
educational campaigns as well as professional continuing education
in order they are aware when managing these people’s health. The
Northeast is clearly a region where efforts should be intensified.
Also, it was made clear how far healthcare use characteristics, as the
frequency of ambulatory visit and use of emergency care, showed to
be linked to the problem of inappropriate use of medicines. The
results demonstrate the importance of the physician–patient rela-
tionship, the so-called ‘joint empowerment’ approach to promoting
adherence and appropriate use of medications in these scenarios
(Náfrádi et al., 2017).
As main limitations of our study, we had information being self-
reported by lay people. On the one hand, we could capture their per-
spective. On the other, some inaccuracies may have been present.
Additionally, despite the data were collected by independently
trained interviewers, since it was presented as a Ministry of Health
study, some inappropriate behaviour may have been under-reported.
The presence of family members during the interview may also have
affected the reliable reporting of some behaviours. It is important to
consider that, as we used a secondary database, the sample was not
designed specifically for the analysis we performed in this article and
variables used here were collected in different parts of the question-
naire. However, we see as positive the possibility of using data from
a nationwide survey to study AUM, which can stimulate others to
do the same. Also, although PNAUM tried to work with a narrow
recall period, 1 month in the case of NCDs, this may have hampered
some recall of information by the respondents.
Finally, a high prevalence of inappropriate use of medicines was
shown, mainly in the non-adherence and inadequate medicines use
behaviour domains, which was associated with both the characteris-
tics of the individuals, treatment and the health system. Individuals’
characteristics are not modified by interventions, but our finding
could support priorities to health education regarding medicines use
and definition of target populations. Also, it is clear that is import-
ant to assure regular visit to physicians. For example, overmedica-
tion was associated with inappropriate use of medicines, suggesting
the need to prioritize medicines counselling strategies. We would
also like point out that the inappropriate use of medicines brings
consequences to the health systems, like a higher use of emergency
care. We hope to have contributed to the inappropriate use of medi-
cines monitoring system.
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Náfrádi L, Nakamoto K, Schulz PJ. 2017. Is patient empowerment the key to
promote adherence? A systematic review of the relationship between
self-efficacy, health locus of control and medication adherence. PLoS One
12: e0186458.
Oliveira MA, Luiza VL, Tavares NUL et al. 2016. Access to medicines for
chronic diseases in Brazil: a multidimensional approach. Revista de Saúde
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